Abstract
Introduction The course of COVID-19 varies from asymptomatic to severe (acute respiratory distress, cytokine storms, and death) in patients. The basis for this range in symptoms is unknown. One possibility is that genetic variation is responsible for the highly variable response to infection. We evaluated how well a genetic risk score based on chromosome-scale length variation and machine learning classification algorithms could predict severity of response to SARS-CoV-2 infection.
Methods We compared 981 patients from the UK Biobank dataset who had a severe reaction to SARS-COV-2 infection before 27 April 2020 to a similar number of age matched patients drawn for the general UK Biobank population. For each patient, we built a profile of 88 numbers characterizing the chromosome-scale length variability of their germ line DNA. Each number represented one quarter of the 22 autosomes. We used the machine learning algorithm XGBoost to build a classifier that could predict whether a person would have a severe reaction to Covid-19 based only on their 88-number classification.
Results We found that the XGBoost classifier could differentiate between the two classes at a significant level p = 2 · 10 as measured against a randomized control and p = 3 · 10 measured against the expected value of a random guessing algorithm (AUC=0.5). However, we found that the AUC of the classifier was only 0.51, too low for a clinically useful test.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This data uses previously collected data from UK Biobank. The original consent was obtained by UK Biobank. Our analysis of the de-identified data has been examined by UC Irvine's IRB. They ruled that our research is not considered "human subjects research" because it uses de-identified data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The original data can be obtained from the UK Biobank.
